NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ:BIIB) Tysabri ...
The Pharma Letter12h
The week in pharma: action, reaction and insight – week to February 21
Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...
FiercePharma9h
Beyond the Diagnosis: Embracing the Humanity Behind Epilepsy Care
Author:  Brad Chapman, Head of U.S. Epilepsy and Rare Syndromes, UCB | Hear from UCB’s Brad Chapman on the importance of inclusion, representation, and understanding in epilepsy and rare syndromes ...
Barchart on MSN9h
2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%
Generally, a “Strong Buy” rating on Wall Street indicates that analysts believe the stock will appreciate and outperform the ...